

Cultured Human Adipocyte Lipolysis Assay Kit for Detection of Both Free Glycerol and Non-Esterified Fatty Acids

CAT# LIP-3; LIP-3-NC

INSTRUCTION MANUAL ZBM0011.03

STORAGE CONDITIONS

Human Adipocytes

All orders are delivered via Federal Express Priority courier at room temperature. All orders must be processed immediately upon arrival.

NOTE:

Domestic customers: Assay must be performed 5-7 days AFTER receipt. International customers: Assay must be performed 3-5 days AFTER receipt

- Reagents & Buffers: 4°C
- Vehicle & Controls: -20°C
- Assay plate A (96-well) cultured human adipocytes: 37°C

For in vitro Use Only

LIMITED PRODUCT WARRANTY

This warranty limits our liability to replacement of this product. No other warranties of any kind, expressed or implied, including without limitation, implied warranties of merchantability or fitness for a particular purpose, are provided by Zen-Bio, Inc. Zen-Bio, Inc. shall have no liability for any direct, indirect, consequential, or incidental damages arising out of the use, the results of use, or the inability to use this product.

ORDERING INFORMATION AND TECHNICAL SERVICES

- Zen-Bio, Inc.
- 3200 Chapel Hill-Nelson Blvd., Suite 104
- PO Box 13888
- Research Triangle Park, NC 27709
- **Telephone** (919) 547-0692
 - Facsimile (FAX) (919) 547-0693
- Toll Free 1-866-ADIPOSE (866)-234-7673
- Electronic mail (e-mail) information@zen-bio.com
- World Wide Web <u>http://www.zenbio.com</u>

•

INTRODUCTION

Lipolysis plays a central role in the regulation of energy balance. Lipolysis is the process in which triglycerides (TG) are hydrolyzed into glycerol and free fatty acids. This process releases free fatty acids (FFA) into the bloodstream where they may be either re-esterified by the adipocyte or travel to other tissues and exert other effects throughout the body. Elevated adipocyte lipolysis has been observed in obese and diabetic individuals (Arner 1996). Excessive free fatty acid production is believed to contribute to insulin resistance in skeletal muscle that is observed in obesity. Hormone sensitive lipase is the rate-limiting enzyme catalyzing triglyceride breakdown. Perilipins, one of the PAT (perilipins, <u>a</u>dipophilin, <u>T</u>IP47 proteins) family of lipid-associated proteins, are implicated in adipocyte lipolysis by mediating the interaction of HSL with the triacylglycerol molecule (Brasaemle *et al.* 2004; reviewed in, Tansey *et al.* 2004.) The presence of these proteins corresponds to lipolytic stimulation in cultured adipocytes (Braemle *et al.* 2004).

The sympathetic nervous system also plays a key role in the regulation of lipid mobilization. The main lipolytic pathway involves beta-agonists (β -agonists), which activate β -adrenergic receptors via the intracellular G_s proteins in adipocytes. This leads to the activation of adenylate cyclase (AC), which then increases cyclic AMP (cAMP) levels. Elevated cAMP acts as a second messenger to activate hormone sensitive lipase (HSL). HSL, the rate-limiting enzyme regulating adipocyte lipolysis, then catalyzes the hydrolysis of triglycerides and results in the release of glycerol and FFA (increased lipolysis). Phosphodiesterases (PDE) are enzymes that hydrolyze cAMP to 5'-AMP (5 prime adenosine monophosphate). This action results in a decrease in lipolysis. PDE inhibitors increase intracellular cAMP levels. 3-isobutyl-1-methylxanthine (IBMX), a non-specific inhibitor of cAMP phosphodiesterases (PDE), is used as the positive control if your test compounds are suspected PDE inhibitors. Isoproterenol, a non-specific β -adrenergic agonist is used as the positive control if your test compounds affect lipolysis via β -adrenergic receptors (Robidoux *et al.* 2004).

This lipolysis assay kit provides the tool to study chemical compounds that may influence lipolysis in cultured human adipocytes.




Figure 1. Overview of adipocyte lipolysis

ABBREVIATIONS:

adenylate cyclase

free fatty acids

protein kinase

insulin receptor

triglyceride

phosphodiesterase

adrenergic receptors

G protein coupled receptor

adenosine monophosphate

adenosine triphosphate

AC

AR

Gs

FFA

PKA AMP

ATP

PDE

ΤG

IR

bloodstream Page 2 of 12

PRINCIPLES OF THE ASSAYS Detection of Free Glycerol

Assessing lipolytic activity by the measurement of glycerol released into the medium. Glycerol released to the medium is phosphorylated by adenosine triphosphate (ATP) forming glycerol-1-phosphate (G-1-P) and adenosine-5'-diphosphate (ADP) in the reaction catalyzed by glycerol kinase. G-1-P is then oxidized by glycerol phosphate oxidase to dihydroxyacetone phosphate (DAP) and hydrogen peroxide (H₂O₂). A quinoneimine dye is produced by the peroxidase catalyzed coupling of 4-aminoantipyrine (4-AAP) and sodium N-ethytl-N-(3-sulfopropyl)m-anisidine (ESPA) with H₂O₂, which shows an absorbance maximum at 540nm. The increase in absorbance at 540nm is directly proportional to glycerol concentration of the sample.


Detection of Non-Esterified Fatty Acids (Free Fatty Acids; FFA)

Assessment of lipolytic activity can also be detected through a coupled reaction to measure non-Esterified fatty acids (NEFA) released by adipocytes. The initial step, carried out by acyl-CoA synthetase (ACS), produces fatty acyl-CoA thiol esters from the NEFA, ATP, Mg, and CoA in the

reaction. The acyl-CoA derivatives react with oxygen in the presence of acyl-CoA oxidase (ACOD) to produce hydrogen peroxide. Hydrogen peroxide in the presence of peroxidase (POD) allows the oxidative condensation of 3-methyl-N-ethyl-N-(β hydroxyethyl)-aniline with 4-aminoantipyrine which forms a purple product that absorbs light at 550nm. This allows the concentration of NEFA to be determined from the optical density measured at 540 - 550nm.

HCOOH + ATP + CoA \xrightarrow{ACS} Acyl-CoA + AMP + PP_i (NEFA)

Acyl-CoA + O_2 \xrightarrow{ACOD} 2,3-trans-Enoyl-CoA + H_2O_2



NOTE:

3 fatty acid molecules are released per triglyceride molecule resulting in a 3:1 fatty acid to glycerol concentration.

ITEMS INCLUDED IN THE KIT

ITEM	DESCRIPTION	Сар	UNIT	QTY	STORAGE		
		Color					
Adipocytes, Plate A	Cultured human subcutaneous		PLATE	1	37°C		
	adipocytes						
Assay Plates	96-well assay plate, blank		PLATE	3			
Wash Buffer			50ml	1	4°C		
Vehicle	0.1% DMSO in LIP-2 Assay Buffer	PURPLE	1 ml /	1	-20°C		
			Vial				
Positive control	Isoproterenol, 10 mM in DMSO. Dilute	BLUE	10 µl /	1	-20°C		
	to 1 μM in Assay Buffer before use!		VIAL				
	(i.e.1 μl in 10 ml Assay Buffer)						
Glycerol Reagent A	Reconstitute with 11.0 ml deionized		BOTTLE	1	4°C		
	water prior to use.						
Tray	For multi-channel pipetters, clear		EACH	4			
	polyvinyl						
Glycerol standard	Glycerol @ 1mM [Dilute with 200 μl	ORANGE	50 μl /	1	-20°C		
	Wash Buffer to make the 200 μ M		VIAL				
	glycerol standard; see page 6 for						
	recommended dilution scheme]						
LIP2/3 Assay Buffer	100ml		100ml	1	4°C		
FFA Standard	1mM Stock. See page 5 for standard	AMBER	100 μl /	1	4°C		
	curve preparation		VIAL				
FFA Diluent A		YELLOW	10.5ML	1	4°C		
FFA Diluent B		PINK	5.5ML	1	4°C		
FFA Reagent A	Reconstitute using 10.5 ml FFA Diluent	YELLOW	BOTTLE	1	4°C		
	A. Discard remainder after 10 days						
FFA Reagent B	Reconstitute using 5.5 ml FFA Diluent	PINK	BOTTLE	1	4°C		
	B. Discard remainder after 10 days						

Other equipment/reagents required but not provided with the kit:

- Multi-channel Pipet, single channel pipet and pipet tips
- Plate reader with a filter of 540 nm
- Incubator at 37°C
- Large gauge needle
- 96 well plate of adipocytes (LIP-3-NC) (cat# SA-1096)
- Tubes for dilution of standards

ASSAY PROCEDURE


- Preadipocytes are plated in 96 well plates and allowed to differentiate under standard Zen-Bio differentiation conditions for 1 week. Upon arrival, remove 150µl of the shipping medium from each well and discard. Place the plate (Plate A) in your incubator for 5-7 days (3-5 days for international customers) to allow the cells to recover from the stress of shipping. To ensure optimal performance, **DO NOT** feed the cells fresh medium during this time. <u>Please observe the</u> <u>cells under a microscope prior to performing the assay</u> [see the photograph in the Certificate of Analysis for the lot # of Plate A].
- 2. Make your stock solution using whatever vehicle is appropriate for your test compounds. Dilute your stock solutions to their final concentration in LIP-2/3 Assay Buffer (100 ml is available). NOTE: if desired, maintain a constant concentration of solvent by preparing all compound dilutions in the highest concentration of that solvent. Dilute your controls in assay buffer. Prepare all vehicles as appropriate for your compounds, 0.1% DMSO has been included as the vehicle for the positive controls. Include the Assay Buffer alone as a vehicle control. PLEASE NOTE: ZEN-BIO DOES NOT RECOMMEND THE USE OF SOLVENTS AT CONCENTRATIONS ABOVE 1%.
- 3. Remove 120 μl medium from each well. Gently add 200 μl Wash Buffer to all wells. Remove 200 μl of the media and Wash Buffer from each well and replace with another 200 μl Wash Buffer.
- 4. Remove all the media and Wash Buffer from the cells from triplicate wells. Treat the cells with 100 μl of the test compounds resuspended in Assay Buffer three (3) wells at a time. Treat with the diluted Isoproterenol as positive control. Use the Assay Buffer alone as one of the vehicle controls. Please be sure to include both the vehicle provided in the kit and your vehicle (if your test compounds are not dissolved in DMSO). The assay should be performed in triplicate.
- 5. Incubate the plate at 37°C-humidified incubator for 3 hours (for time course experiments the longest time point recommended is 5 hours). Note: Treatment times longer than 3 hours will result in significant fatty acid reutilization by the adipocytes and may decrease signal relative to total lipolysis activity.

A. DETECTION OF NON-ESTERIFIED FATTY ACIDS

1. Prepare the standard curve using the FFA STANDARD SOLUTION as follows:

Briefly spin down the contents of the free fatty acid standard tube before reconstitution. Standards are: 0, 1.4, 4.1, 12.3, 37, 111, and 333 μ M fatty acid. Prepare as follows:

The kit standard solution is the 1.0 mM standard. Pipette 60 μ l of Dilution Buffer into 6 tubes (not provided). Pipette 30 μ l of the FFA Standard Stock into a tube labeled 333 μ M. Prepare a dilution series as depicted below. Mix each new dilution thoroughly before proceeding to the next. The Dilution Buffer alone serves as the zero standard.




- Add 10.5ml FFA Diluent A to the FFA Reagent A bottle and gently invert. DO NOT VORTEX! Store any remaining solution at 2-8°C; it is stable for 10 days after reconstitution refrigerated (2-8°C).
- 3. At the end of the incubation, 30 μl of the conditioned media is removed and transferred to the corresponding well of a blank plate for assessment of non-esterified fatty acids. [This is most easily accomplished using a multi-channel pipet.] Add 30 μl of each standard to empty wells.
- Add the reconstituted FFA Reagent A to one of the disposable trays provided in the kit. Add 100 μl of FFA Reagent A to each well. Gently shake the plate to ensure mixing. Place in a 37 °C incubator for 10 minutes.
- Add 5.5 ml FFA Diluent B to the FFA Reagent bottle and gently invert. Store any remaining solution at 2-8°C; it is stable for 10 days after reconstitution refrigerated (2-8°C).
- 6. Add the reconstituted FFA Reagent B to the other disposable tray provided in the kit. Add 50 μ l of FFA Reagent B to each well. Gently shake the plate to ensure mixing. Place in a 37 °C incubator for 10 minutes.
- 7. Allow the plate to equilibrate to room temperature for 5 minutes. During this time, ensure that there are no bubbles in the solution mixture. Use a large gauge needle or clean pipet tip to pop any bubbles as this will result in inaccurate absorbance readings.
- 8. The optical density of each well is then measured at 540 nm.

B. DETECTION OF FREE GLYCEROL

1. One hour prior to the assay, prepare the glycerol standards as follows:

Briefly spin down the contents of the glycerol standard tube before reconstitution. Pipette 200 μ l of Wash Buffer into the 1 mM glycerol standard tube provided and mix well by vortexing. This produces a diluted stock glycerol standard of 200 μ M. Pipette 125 μ l of wash buffer into 6 tubes (not provided). Using the newly diluted stock glycerol solution, prepare a dilution series as depicted below. Mix each new dilution thoroughly before proceeding to the next. The 200 μ M stock dilution serves as the highest standard, and the wash buffer serves as the zero standard.




- 2. Also at this time prepare the Glycerol Reagent A by adding 11.0 ml room temperature deionized water per bottle and gently invert. DO NOT VORTEX! Use a pipet to ensure that the powder is completely dissolved. Store at room temperature. If using a Reagent A solution previously prepared and stored at 2-8°C, also bring to room temperature. Make sure there is enough Reagent A from one solution to treat all the points in the assay. It may be necessary to combine solutions. Store in a light protected bottle. Reconstituted Glycerol Reagent A is stable for 60 days refrigerated (2-8°C); store any remaining solution refrigerated (2-8°C).
- 3. At the end of the incubation, an additional 50 μl of the conditioned media is removed and transferred to the corresponding well of a blank plate for assessment of free glycerol. [This is most easily accomplished using a multi-channel pipet. Add 50 μl of each glycerol standard to any remaining empty wells in one of the blank assay plates.
- 4. OPTION: to determine if the compound alone reacts with the Glycerol Reagent A, prepare a fresh plate (not included in kit) containing 50 μl of the compound. This plate can be incubated at 37°C with the treated cells. When performing the assay, add 50 μl of Glycerol Reagent A following the instructions in Steps 5 and 6.
- 5. Add the reconstituted Glycerol Reagent A solution to one of the disposable trays provided in the kit. Add 50 μl of Reagent A to each well of Plate B and Plate C (if used). Gently, pipet up and down once to mix. Pop the bubbles using a large gauge needle or a clean pipet tip. The plate is then incubated at 25°C (room temperature) for 15 minutes.
- 6. The optical density of each well is then measured at 540 nm.

FATTY ACID STANDARD CURVE

Generate standard curve: see example below

[DO NOT use this standard curve to generate your data. This is an example.]

Subtract the OD value of the 0μ M standard from all OD values including the standard curve. . Note: 1mM standard is commonly omitted from analysis due to lack of linearity between 333 μ M and 1mM. Optionally, a 4-parameter fit may be used to calculate standard curve.



y = 0.0019x - 0.0045 $R^2 = 0.9995$

Data are expressed as μ M free fatty acids released.

OPTION: express data as Fold induction over appropriate vehicle Fold induction = μ M free fatty acids SAMPLE μ M free fatty acids VEHICLE

The R^2 value should be equal or greater then 0.98 for the standard curve to be valid. Any R^2 values below 0.98, must have the standard curve run again.


μM standard

GLYCEROL STANDARD CURVE

Generate standard curve: see example below

[DO NOT use this standard curve to generate your data. This is an example.]

Subtract the OD value of the 0μ M standard from all OD values including the standard curve.



slope =	0.0034		
intercept=	0.0075		
r ² =	0.9985		

y = observed O.D. minus the blank

x = concentration of glycerol in μM

To calculate x for each y, (i.e. to change the observed O.D. into glycerol concentration) use the following equation:

y=(slope) times (x) plus intercept

y=mx+b so x=(y-b)/m

x=(y - 0.0075)/0.003 where 0.003= slope of the line and 0.0075= y intercept. Be careful to enter the proper sign for the y intercept value as it may be a negative number.

Any OD values greater than the highest standard (200 μ M) should be suspect. The compound should be re-assayed using a lower dose of the compound at treatment OR a dilute solution of the condition medium at the time of the assay.

The R^2 value should be equal or greater then 0.98 for the standard curve to be valid. Any R^2 values below 0.98, must have the standard curve run again.

Data are expressed as μ M glycerol released.

OPTION: express data as Fold induction over appropriate vehicle Fold induction = μM glycerol SAMPLE μM glycerol VEHICLE


APPENDIX A: PLATE LAYOUT

т	G	т	m	D	C	ω	A	
								-
								2
								ы
								4
								ъ
								6
								7
								ø
								9
								10
								1
								12

APPENDIX B: PROCEDURE FLOWCHART

Remove 150µl of the shipping medium and place in your incubator for 5-7 days (3-5 days for international customers) **ON DAY OF ASSAY** Make all test compound dilutions in Assay Buffer. Plate A 120 ul media Remove 120 $\mu l\,$ media from all wells. 000000000000 Add 200 µl Wash Buffer to all wells. 200 µl Wash Buffer Plate A .200 µl Wash Buffer Remove 120 µl media & Wash Buffer. Add another 200 µl Wash Buffer to all wells. Add another 200 µl Wash Buffer Plate A Remove 3 wells at a time Remove all media & Wash Buffer. Add 100 μ l treatments/controls to 3 wells at a time. Add treatments 3 wells at a time Incubate 3-5 hours at 37°C. FREE FATTY ACID DETECTION Plate A Assay Plate **30** µl 00000000 Remove 30 $\mu\text{l/well}$ conditioned media from Plate A to Plate B. 100ul/well Reconstitute FFA Reagent A using Diluent A. FA Reagent A Add 100µl/well. Incubate 10 minutes @ 37°C. Plate C may be necessary for the assay standards of if al 96 wells 50µl/well of Plate A are FF A Reagent B Reconstitute FFA Reagent B using Diluent B. used. Add 50µl/well. Incubate 10 minutes @ 37°C. Place at room temp. for 5 minutes. Pop any bubbles in each well using a clean pipet tip or large gauge needle. Measure the optical density of each well at 540 nm using a spectrophotometer plate reader.

FREE GLYCEROL DETECTION



REFERENCES

- 1. Arner P (1996) Diabetes Rev 4(4):450-463.
- 2. Botion LM & Green A. Diabetes (1999) 48:1691-1697
- 3. Brasaemle DL, Dolios G, Shapiro L, Wang R. (2004) J Biol Chem 279(45): 46835-42.
- 4. Cooper DMF, Schlegel W, Lin MC, Rodbell M. (1979) J Biol Chem 254(18):8927-8931.
- 5. Dyck DJ Can J Appl Physiol (2000) 25(6):495-523.
- 6. Kordik CP & Reitz AB. J Medicinal Chem (1999) 42(2):181-201.
- Rieusset J, Chambrier C, Bouzakri K, Dussere E, Auwerx J, Riou J-P, Laville M, Vidal H. Diabetologia (2001) 44:544-554.
- 8. Robidoux J, Martin TL, Collins S. (2004) Ann Rev Chem 253: 7570-7578.
- 9. Scriba D, Aprath-Husmann I, Blum WF, Hauner H. Eur J Endocrinol (2000) 143:439-445
- 10. Snyder PB Emerging Therapeutic Targets (1999) 3(4): 587-599.
- 11. Tansey JT, Sztalryd C, Hlavin EM, Kimmel AR, Londos C. (2004) IUBMB Life 56(7):
 - 379-85.